Navigation Links
Bionovo to Raise $3 Million Through Registered Direct Offering
Date:10/1/2010

EMERYVILLE, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI), a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.  The Company agreed to sell a total of 2,727,270 shares, at a price of $1.10 per share. In addition, the Company agreed to issue 2,045,451 warrants to purchase shares. The warrants will be exercisable six (6) months after issuance at $1.64 per share and will expire five (5) years from the date of issuance.  The shares of common stock and warrants are immediately separable and will be issued separately.

Bionovo estimates that net proceeds from the offering will be approximately $2.8 million, after deducting placement agents' commissions.  The Company intends to use the net proceeds from the sale of the securities primarily for general corporate purposes, including clinical trial, research and development, general and administrative and manufacturing expenses.

William Blair & Company, L.L.C. is acting as the exclusive placement agent.

The securities described above are being offered pursuant to a registration statement on Form S-3 previously declared effective by the Securities and Exchange Commission on June 17, 2010.  The transaction is expected to close on or about Wednesday, October 6, 2010, subject to customary closing conditions.

A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may be obtained by contacting William Blair & Company, L.L.C. at 222 West Adams, Chicago, Illinois 60606, attention: Equity Capital Markets at 312-236-1600.  A copy of the prospectus supplement relating to the offering and
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo to Present at the JMP Securities Healthcare Conference
2. Bionovo to Present at Cambria Capital Investor Meeting
3. Bionovo Receives Positive Guidance from FDA on Menerba®
4. Bionovo Announces Reverse Stock Split
5. Bionovo Announces Publication Describing Menerbas Effect on Neural Pathways Related to Temperature Regulation
6. Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
7. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
8. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
9. Bionovo Announces 2009 Highlights and Year-End Financial Results
10. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
11. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 ... Lilly and Company (NYSE: LLY ) and ... positive results from DURATION-2, the second in a series ... once weekly, an investigational diabetes therapy, as compared to ...
... new study, published in the Journal of Medicinal ... 8 grams (1/3 ounce) of "Sun Chlorella A" daily ... total cholesterol, and fasting blood glucose levels.For a 12-week ... A" tablets each morning and evening. Seventeen subjects ...
Cached Medicine Technology:Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 2Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 3Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 4Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 5Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 6First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... Food and Drug Administration (FDA) have approved the drug Femara ... breast cancer among post menopausal women//. ,Various studies ... result of these studies was published in the December 29 ... said that the Novartis drug Femara was very efficient in ...
... of swallows in Malawi had raised fears about the possibility of ... // have revealed a negative bird flu infection status of ... ,"We have tested samples that were sent to us ... swallows, which were dying in large numbers. We don't know what ...
... enterotoxin produced by the bacteria Vibrio cholerae, which leads to ... has occurred in two cities in // ... infected with the bacteria in two districts of Chikomba and ... is high in conditions where treatment is not given. The ...
... in attitudes toward circumcision in Swaziland, which has one of ... one of the highest HIV prevalence rates. ... sudden comeback in the country since the publication of a ... risk of contracting HIV. ,According to the ...
... children is a major health hazard. More-so when homes use ... lead // poisonings in children, by suggesting new requirements ... years, Lead, a highly toxic metal has been used as ... spectrum of health problems ranging from cognitive impairment and learning ...
... Kerr has urged to increase awareness of organ donation among ... loss dying // due to organ failure and non-availability ... heavy human loss of young people and their lives depend ... Donor cards and registration with NHS organ donor register, which ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Child-friendly initiative For Lead-Based Paint Work: EPA, USA 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: